Pharma Industry Trends Ppt2
Pharma Industry Trends Ppt2
Pharma Industry Trends Ppt2
Pharma Industry Trends IVth Year B. Pharm. + MBA Pharmtech Lecture 2 : March 2012
Total Pharma
53,803
100.00
+15
Rank
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Brand
Corex Pfizer Human Mixtard Abbott Phensedyl Abbott Voveran Novartis Augmentin GSK Revital Ranbaxy Monocef Aristo Dexorange Franco India Taxim Alkem Liv-52 Himalaya Volini Ranbaxy Mox Ranbaxy Spasmo Proxyvon Wockhardt Becosules Pfizer Betadine Win Medicare Zifi Fulford Asthalin Cipla Clavam Alkem Calpol GSK Taxim-O Alkem
Jan 12 Rank 1 2 5 4 3
Primarily driven by a large population Evolving patient demographics Increasing health care expenditure Growing urbanisation Rising life expectancy and Active private-sector participation in all sectors of Indian Healthcare
New Chemical Entity & Drug Discovery OTC & New Drug Delivery Systems Value- Added and Branded Generics Conventional Dosage Forms Intermediate & Bulk Substances Commodity Generics
Opportunities exist ranging from the low-value added segment, comprising of NDDS ($134 billion opportunity by 2013) Generics ($135 billion worth of product expiring before 2015) and Biosimilars ($115 billion worth of biologics expiring by 2015) High value New Chemical Entity (NCE)/New Biopharmaceutical Entity segment.
Thus, domestic companies can look forward to pursue all these opportunities and build capabilities to conduct drug discovery and in house development.
The advent of the product patent regime in 2005 instilled confidence in the countrys IP regime. With renewed confidence, large pharma MNCs are now looking to launch their patented drugs in India and such product launches are expected to increase further in future.
Pharma MNCs :
Changing the tune for India
Differential pricing strategy to strengthen market reach:
In a bid to compete with domestic generic players, pharma MNCs are launching patent-protected drugs in India at relatively low price points than those in developed markets. Simultaneously, a differential pricing strategy is helping these MNCs to enhance their market reach by addressing affordability issues. Drugs such as Diovan (for bp, Novartis), Januvia (for type II diabetes, Merck Sharp & Dohme), and Galvus (also for Type II diabetes, Novartis) are being sold at discounts of up to 80 per cent on global prices.
In September 2010, Johnson & Johnson (J&J) launched a mobile health initiative for expectant mothers in India. Mobile Health for Mothers provides free text messages on prenatal care, appointment reminders and calls from health coaches.
Such noble initiatives can be expected to help pharma MNCs further augment their brand awareness in the domestic market and help tap the segments growth potential.